Loading patent…
OwnerPeter Blume-Jenseninventor
Estimating the term…
The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.
A method of identifying a responder patient population for treatment with an exogenous agent comprising:
A method for identification of a mammal responsive to a drug for treating a disease comprising:
A method for identifying a mammalian population responsive to a drug for treating a disease comprising:
A kit for identifying a mammalian population responsive to treatment with an exogenous agent comprising:
A kit for identifying a mammal responsive to a drug for treating a disease comprising:
A kit for identifying a mammalian population responsive to a drug for treating a disease comprising:
Dependencies are inferred from the claim text.